{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-035743","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2026-08-03T11:15:25+00:00","discovered_at":"2026-08-03T11:20:00.506015+00:00","generated_at":"2026-08-03T11:20:11.202947+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cocrystal Pharma raises $5M from OPKO Health; norovirus Phase 1b data expected Q4 2026","bullets":["Sold 5,474,053 shares to OPKO at $0.9134/share, gross proceeds $5.0M, no warrants.","Proceeds to fund preclinical/clinical programs, including norovirus Phase 1b trial with topline data by end of Q4 2026.","Dr. Phillip Frost, Chairman/CEO of OPKO, is co-founder, director, and principal stockholder of Cocrystal.","Private placement under Section 4(a)(2) and Regulation D; shares unregistered."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-035743","json":"https://secwatch.observer/filing/0001493152-26-035743.json","markdown":"https://secwatch.observer/filing/0001493152-26-035743.md","text":"https://secwatch.observer/filing/0001493152-26-035743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226035743/0001493152-26-035743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226035743/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T11:20:11.202947+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}